Patent 9801889 was granted and assigned to Incyte on October, 2017 by the United States Patent and Trademark Office.
The present disclosure relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR4 enzyme and are useful in the treatment of FGFR4-associated diseases such as cancer.